AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

BACKGROUND: Device-detected atrial fibrillation (also known as subclinical atrial fibrillation
or atrial high-rate episodes) is a common finding in patients with an implanted cardiac …

BACKGROUND: There is ambiguity whether frail patients with atrial fibrillation managed with
vitamin K antagonists (VKAs) should be switched to a non–vitamin K oral anticoagulant …

Postoperative atrial fibrillation (POAF) is the most common type of secondary atrial fibrillation
(AF) and despite progress in prevention and treatment, remains an important clinical …

Background: There is uncertainty surrounding the use of direct oral anticoagulants (DOACs)
in patients with kidney dysfunction. Methods: Using the COMBINE AF (A Collaboration …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

Abstract Factor XI/XIa (FXI/FXIa) represents a potential target for improved precision in
anticoagulation because it is involved primarily in thrombus formation and plays a much …

Aims The prognosis of patients with atrial fibrillation (AF) and ischemic stroke while taking
oral anticoagulation is poorly understood. This study aimed to characterize the outcomes of …

FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …